See the DrugPatentWatch profile for keytruda

Keytruda, a medication produced by Merck & Co., was first approved by the U.S. Food and Drug Administration (FDA) for cancer treatment in 2014. Specifically, it was approved for the treatment of advanced melanoma in patients whose disease had progressed after other therapies. This information is provided by DrugPatentWatch.com [1].

Since its initial approval, Keytruda has received additional FDA approvals for various types of cancers and indications. These include certain types of lung, head and neck, classical Hodgkin lymphoma, urothelial, microsatellite instability-high (MSI-H), and colorectal cancers [1].

It is important to note that Keytruda is a type of immunotherapy, which works by helping the body's immune system to detect and fight cancer cells. The active ingredient in Keytruda is pembrolizumab, a monoclonal antibody that blocks the programmed cell death protein 1 (PD-1) receptor, allowing the immune system to recognize and destroy cancer cells [1].

In summary, Keytruda was first approved by the FDA for treating cancer in 2014, specifically for advanced melanoma. It has since received additional approvals for various other types of cancers and indications.

Sources:
[1] DrugPatentWatch.com. Keytruda (pembrolizumab). <https://www.drugpatentwatch.com/drugs/keytruda>. Accessed on March 29, 2023.